How improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes Challenges healthcare marketers face in ...
Harpreet Gill, vice president of real-world solutions - project management at ICON, discussesthe progress and challenges in advancing data-driven tools and approaches in decentralized clinical trials, ...
In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses the recent DEA extensions of telehealth for controlled substances and new treatment modalities ...
Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape ...
With increasing cases of disinformation across social media blurring the lines of what’s credible and real, how can pharma break through the noise and build back public trust? Biopharmaceutical ...
New technology is making it easier for more companies to embrace telehealth, which in turn is providing more opportunities for pharma companies to interact with HCPs and patients. Peter Ax, founder ...
John Hood, CEO, Endeavor BioMedicines discusses the key differences between ENV-101 and currently approved IPF treatments. PE: How does the initiation of the WHISTLE-PF trial fit into Endeavor ...
In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome. Pharmaceutical Executive recently brought together a group of experts to discuss the ...
GLP-1s are the most discussed drug of 2024. While they were initially developed to treat diabetes, the drug’s ability to help with weight loss has made them extremely popular. So much so that in 2023, ...
The molecule is an investigational pre-clinical oral GLP-1 receptor agonist. Merck entered into an agreement with Hansoh Pharma in which the former company will obtain the global license agreement for ...
In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses regulatory challenges and opportunities that telehealth companies face in 2025. In this ...
Amid the end of a national GLP-1 shortage, the FDA will now require all compounding, distributing, or dispensing of compounded tirzepatide injections to end within 90 days. The FDA has updated its ...